2315 Stock Overview
A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2315 from our risk checks.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$6.97 |
52 Week High | HK$13.50 |
52 Week Low | HK$5.74 |
Beta | 0.67 |
11 Month Change | 10.63% |
3 Month Change | -8.65% |
1 Year Change | -37.43% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -73.19% |
Recent News & Updates
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking
Apr 03Shareholder Returns
2315 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -6.6% | -0.4% | -1.0% |
1Y | -37.4% | 2.7% | 20.3% |
Return vs Industry: 2315 underperformed the Hong Kong Biotechs industry which returned 2.7% over the past year.
Return vs Market: 2315 underperformed the Hong Kong Market which returned 20.3% over the past year.
Price Volatility
2315 volatility | |
---|---|
2315 Average Weekly Movement | 12.3% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 8.9% |
10% most volatile stocks in HK Market | 18.9% |
10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2315 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2315's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,040 | Yuelei Shen | biocytogen.com.cn |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
2315 fundamental statistics | |
---|---|
Market cap | HK$2.78b |
Earnings (TTM) | -HK$266.79m |
Revenue (TTM) | HK$876.01m |
3.2x
P/S Ratio-10.4x
P/E RatioIs 2315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2315 income statement (TTM) | |
---|---|
Revenue | CN¥800.58m |
Cost of Revenue | CN¥213.99m |
Gross Profit | CN¥586.58m |
Other Expenses | CN¥830.40m |
Earnings | -CN¥243.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.61 |
Gross Margin | 73.27% |
Net Profit Margin | -30.46% |
Debt/Equity Ratio | 53.1% |
How did 2315 perform over the long term?
See historical performance and comparison